AZ’s Farxiga reduces heart failure, but misses on CV events

AstraZeneca plc (LSE:AZN; NYSE:AZN) presented details of its 17,160-patient Phase III DECLARE-TIMI 58 cardiovascular outcomes trial (CVOT) showing that diabetes drug Farxiga dapagliflozin's primary CV benefit was limited to reducing hospitalizations due to heart failure.

The new details presented Saturday at the American Heart Association (AHA) meeting in Chicago showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor lagging behind Jardiance empagliflozin and Invokana canagliflozin on key efficacy measures including reductions in MACE and heart failure. The DECLARE-TIMI 58 data were also published in the New England Journal of Medicine...